linjc16/ctgov huggingface dataset:
The Influence of Hospital Environment on Eyes Infections in Medical Staff

Study Overview
=================
Brief Summary
-----------------
The investigators want to find out if there is any difference between the microbiotic flora lining the conjunctiva of medical staff that work in the hospital and others who do not work in the hospital.

Conditions
-----------------
Eye Infections

Intervention / Treatment
-----------------
* Other: microbiologic sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy medical workers. Exclusion Criteria: any ocular disease. previous ocular surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: medical staff<br> | Other: microbiologic sample<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| significant difference in the bacterial flora of conjunctiva |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
conjunctival flora
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine

Study Overview
=================
Brief Summary
-----------------
To evaluate the persistence of immune response 5 years and 6 years after the first vaccine dose.

Detailed Description
-----------------
Open, randomised, long-term antibody persistence studies, conducted in 2 centers. Immune persistence was compared between subjects who received two doses of GSK Biologicals combined hepatitis A and hepatitis B vaccine at either 0, 6 month schedule or 0, 12 month schedule. These long-term follow-up studies involved taking blood samples at approximately 5 and 6 years after the primary vaccination of combined hepatitis A and B vaccine, to assess antibody persistence and a retrospective safety follow-up.

Official Title
-----------------
Evaluate the Persistence of Immune Response of GSK Biologicals' TWINRIX™ ADULT, Administered According to 0,6 Month Schedule and 0,12 Month Schedule, in Volunteers Aged 12-15 Years Inclusive at the Time of First Vaccine Dose

Conditions
-----------------
Hepatitis B, Hepatitis A

Intervention / Treatment
-----------------
* Biological: Combined Hepatitis A and B vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who received GSK Biologicals' combined hepatitis A and B vaccine in the primary study (HAB-082). Subjects were aged 12 to 15 years at the time of the first vaccination.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Combined Hepatitis A and B vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune persistence in terms of anti-HAV and anti-HBs antibodies and GMCs, 5 and 6 years after administration of first vaccine dose. An additional dose of the study vaccine will be given (between 6 to 12 months after the Year 6 time point) to subjects who |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To record the SAEs that was reported since the last time point. |  |  |
Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
For patients with thyroid gland nodule, fine-needle aspiration biopsy has been proved to be an efficient tool for thyroid cancer diagnosis. However, it is somewhat an invasive procedure and is subject to sampling and analysis uncertainties. Thus, improved, more reliable criteria for determining which nodule should be be aspirated are needed. Ultrasound elastography has been shown to be useful in the differential diagnosis of breast and prostate cancers. Ultrasound elastography also may discriminate malignant from benign nodule.

Detailed Description
-----------------
To prospectively evaluate the elastographic appearance of thyroid cancer and explore the potential sensitivity and specificity of elastography for differentiating benign and malignant tumors, with histopathologic analysis as the reference standard.

Official Title
-----------------
Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer

Conditions
-----------------
Elastography, Thyroid Nodule

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - The patients with thyroid nodule who are supposed to take fine needle aspiration biopsy Exclusion Criteria: - The patients who do not want to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FNAB of Thyroid nodule<br>The Patients with thyroid nodule who are scheduled for FNAB | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performance of elastography using in-vivo compression for detection of thyroid cancer | Measuring ECI(Elasticity contrast index) of thyroid nodule by ultrasound elastography | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of the parameters which could have influence on the diagnostic performance of ultrasound elastography using in-vivo compression | Analysis of clinical characteristics of thyroid nodules and patients which are related to the diagnostic performance of ultrasound elastography | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elastography, Thyroid nodule
Health Effects of Particulate Acids in Late Adolescence

Study Overview
=================
Brief Summary
-----------------
This study was designed to follow a group of adolescents who were previously examined by questionnaire and pulmonary function tests when they were aged 8-10 years old. Approximately 50% of the population in 10 towns were seen again at age 17-18. Questionnaires and pulmonary function were repeated. The hypotheses being tested related to whether the previously seen levels of pulmonary function that were related to pollution levels in the towns persisted as the lungs of these children grew and whether dietary antioxidants influences level of attained pulmonary function.

Conditions
-----------------
Airway Obstruction, Cough

Participation Criteria
=================
Eligibility Criteria
-----------------
Children seen in a previous study at ages 8-10 from selected cities

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FEV, Smoking, antioxidents, lung growth
Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of an adjuvanted influenza vaccine in elderly subjects.

Official Title
-----------------
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2005-2006, When Administered to Elderly Subjects.

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: influenza vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 65 years of age or older and in good health Exclusion Criteria: Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure. any acute disease or infections requiring systemic antibiotic or antiviral therapy hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine known or suspected (or high risk of developing) impairment/alteration of immune function within the past 7 days

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: influenza vaccine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection. |  |  | 
| Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection. |  |  | 
| Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
influenza, elderly, vaccine
ED Lung Protective Ventilation to Reduce Complications

Study Overview
=================
Brief Summary
-----------------
Early mechanical ventilation, if delivered with injurious settings, can lead to pulmonary complications, such as acute respiratory distress syndrome (ARDS). Mechanical ventilation in the emergency department (ED) has been studied infrequently when compared to the intensive care unit; however, data suggests that ED-based mechanical ventilation has significant room for improvement and may also be a causative factor in ARDS incidence.

Detailed Description
-----------------
This is a before-after study examining the impact of implementing lung protective ventilation in the emergency department.

Official Title
-----------------
The Effect of Lung Protective Ventilation Initiated in the Emergency Department on the Incidence of Pulmonary Complications and Clinical Outcomes

Conditions
-----------------
Mechanical Ventilation, Ventilator-associated Conditions, ARDS

Intervention / Treatment
-----------------
* Procedure: lung protective ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mechanically ventilated via an endotracheal tube in the ED Exclusion Criteria: death in the ED, death or discontinuation of ventilation within 24 hours, chronic mechanical ventilation, ARDS while in the ED transfer to another hospital.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pre-intervention group<br>mechanically ventilated patients before implementation of ED lung protective ventilation | |
| Intervention group<br>mechanically ventilated patients after implementation of ED lung protective ventilation | Procedure: lung protective ventilation<br>* Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients That Experience Pulmonary Complications After Admission From the Emergency Department |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients That Die During the Hospitalization |  | Patients will be followed for the duration of hospital stay |
Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images

Study Overview
=================
Brief Summary
-----------------
mPDia is a software that has been pre-learned based on a neurodegenerative parkinsonism diagnosis model using Nigrosome 1 MRI images, and clinical decision support system for diagnosing neurodegenerative parkinsonism by automatically analyzing Nigrosome 1 MRI images by assisting the medical team. The specific aims of this study are to evaluate efficacy of mPDia for neurodegenerative Parkinsonism compared to the sensitivity and specificity levels of 18F FP-CIT PET/CT which is currently used to diagnose neurodegenerative parkinsonism.

Official Title
-----------------
An Open Label, Multicenter, Retrospective, Pivotal Trial to Evaluate the Efficacy of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images

Conditions
-----------------
Diagnoses Disease

Intervention / Treatment
-----------------
* Device: mPDia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria(Normal cohort): Adults over 19 years old 3T nigrosome 1 MRI acquired 18F FP-CIT PET/CT are confirmed to be normal The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism Inclusion Criteria(Abnormal cohort): Adults over 19 years old 3T nigrosome 1 MRI acquired 18F FP-CIT PET/CT are confirmed to be abnormal The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism Exclusion Criteria: Patients with other brain diseases except parkinsonism Who have anatomical abnormality in MRIs etc. Who have other causes of tremor(e.g., thyroid disease) Patients with lesion in basal ganglia(e.g., vascular parkinsonism, hydrocephalus and Wilson's disease)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Abnormal<br>The person who visits parkinsonism symptoms and has been diagnosed with neurodegenerative parkinsonism | Device: mPDia<br>* Clinical decision support system for diagnosing neurodegenerative parkinsonism<br>|
| Normal<br>The person who visits parkinsonism symptoms but is not or is normal for neurodegenerative parkinsonism | Device: mPDia<br>* Clinical decision support system for diagnosing neurodegenerative parkinsonism<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and specificity of mPDia | Sensitivity and specificity of mPDia in diagnosis of neurodegenerative parkinsonism based on golden standards | Within 4 weeks after collecting data | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neurodegenerative Parkinsonism
Voriconazole-Induced QT Interval Prolongation: A Prospective Study

Study Overview
=================
Brief Summary
-----------------
The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.

Official Title
-----------------
Voriconazole-Induced QT Interval Prolongation: A Prospective Study

Conditions
-----------------
Voriconazole Induced QT Interval Prolongation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: oral or IV treatment with voriconazole Exclusion Criteria: No data prior to initiation of voriconazole treatment on QT interval (baseline ECG) Renal insufficiency or dialysis treatment

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QT interval prolongation |  | up to three months of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
voriconazole, ECG, arrhythmia
Patient Surveys - What Patients Want

Study Overview
=================
Brief Summary
-----------------
This study is to gain insight into patients' preferences considering satisfaction surveys, specifically asking for their most pressing topics and their preferred survey technique.

Detailed Description
-----------------
The practice of patient surveys for quality management is revised at the University Hospital Basel (USB). One aspect is a more versatile data acquisition via online portals and/or paper questionnaires, another aspect is the content of questions and the assessment of demographic data. In this situation a tentative survey on their preferences in this context was realised in patients who were treated in autumn 2016 at the Department of Orthopaedics and Trauma Surgery (DOTS) using a cover letter informing them about the nature of the survey. They were asked to provide few basic demographic data, they were furthermore asked whether they favoured surveys by the USB and if so with which focus. Finally they had the option to name three central topics for feedback and to quantify the number of questionnaires they had so far received by the USB. The survey could be completed in a paper and survey monkey based internet version accessible via a Quick Response (QR) code or link.

Official Title
-----------------
Patient Surveys - What Patients Want

Conditions
-----------------
Patient Survey

Intervention / Treatment
-----------------
* Other: patient satisfaction survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All data from completed survey sheets (paper questionnaires) and online forms are included Exclusion Criteria: no exclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: patient satisfaction survey|Patient survey completed in a paper or survey monkey based internet version accessible via a QR code or link|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients' preferences considering preferred survey technique | patients' preferences considering paper questionnaire or survey monkey based internet version accessible via a QR code or link | after out- or inpatient treatment at the DOTS in a three months period in autumn 2016 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients' preferences asking for their most pressing topics | option to name three central topics for feedback | after out- or inpatient treatment at the DOTS in a three months period in autumn 2016 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
quality management, paper questionnaires, satisfaction surveys, survey technique, online questionnaires